Pharmafile Logo

clarkhealthcommunications

- PMLiVE

Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS

The neurological disorder affects approximately 2.9 million people globally

EU flag

CHMP recommends Galderma’s nemolizumab for atopic dermatitis and prurigo nodularis

The drug has been recommended for use in patients with moderate-to-severe cases of the skin diseases

- PMLiVE

Gilead appoints Dietmar Berger as chief medical officer

Berger most recently served as chief medical officer and global head of development at Sanofi

- PMLiVE

The need for a human touch in an AI world

AI is shooting for the moon and the stars but the real benefits come from anchoring it to the human voice

- PMLiVE

AbbVie’s Parkinson’s disease candidate tavapadon shows promise in phase 3 trial

More than ten million people worldwide are living with the neurodegenerative disorder

- PMLiVE

Merck shares positive phase 3 results for Keytruda/Lynparza regimen in ovarian cancer

Ovarian cancer is the seventh most common cancer in women globally

- PMLiVE

Tackling the growing burden of chronic obstructive pulmonary disease in the UK

Iona Everson from PMGroup spoke to John Forni, Country Medical Director at Sanofi UK & Ireland, about the escalating challenges of treating chronic obstructive pulmonary disease (COPD) in the UK...

- PMLiVE

Eli Lilly announces $3bn expansion to US injectables manufacturing facility

The investment will help Lilly meeting the growing demand for its diabetes and obesity medicines

- PMLiVE

NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree

Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

- PMLiVE

Amar Urhekar announced as CEO of Avalere Health

Global strategic partner in healthcare, Avalere Health, is proud to announce the appointment of Amar Urhekar as its new Chief Executive Officer.

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links